The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial

Itolizumab is a humanized anti-CD6 monoclonal antibody (mAb) that has previously shown encouraging results, in terms of safety and positive clinical effects, in a 6-week monotherapy clinical trial conducted in rheumatoid arthritis (RA) patients. The current Phase I study evaluated the safety and cli...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2018

Institución:

Universidad de Medellín

Repositorio:

Repositorio UDEM

Idioma:

eng

OAI Identifier:

oai:repository.udem.edu.co:11407/4574

Acceso en línea:

http://hdl.handle.net/11407/4574

Palabra clave:

CD6; clinical trial; itolizumab; Phase I; rheumatoid arthritis

Rights

License

http://purl.org/coar/access_right/c_16ec